Non-small Cell Lung Cancer (NSCLC) Clinical Trials in Oklahoma City, Oklahoma

4 studies are recruiting for non-small cell lung cancer (nsclc) in Oklahoma City, Oklahoma right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

    The purpose of this study is to evaluate the efficacy of Pumitamig versus Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Local Institution - 0418, Oklahoma City, Oklahoma
    Locations
    279 in total
    Run by
    Bristol-Myers Squibb

    See if you can join NCT07361510 on ClinicalTrials.gov

  2. Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

    This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Oklahoma, Oklahoma City, Oklahoma
    Locations
    55 in total
    Run by
    Revolution Medicines, Inc.

    See if you can join NCT06128551 on ClinicalTrials.gov

  3. KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

    This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyltransferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with advanced solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    OU Stephenson Cancer Center, Oklahoma City, Oklahoma
    Locations
    38 in total
    Run by
    Kura Oncology, Inc.

    See if you can join NCT06026410 on ClinicalTrials.gov

  4. A Study of NX-1607 in Adults With Advanced Malignancies

    This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Oklahoma, Oklahoma City, Oklahoma
    Locations
    17 in total
    Run by
    Nurix Therapeutics, Inc.

    See if you can join NCT05107674 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.